Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver

Recruiting now · Not applicable

Conditions studied: Non-Alcoholic Fatty Liver Disease

In brief

The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.

Key facts

Study ID

NCT06735118

Run by

Yunnan Cancer Hospital

People needed

120

Starts

2023-12-25

Expected to finish

2024-12-30

Last updated by the study team

2024-12-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• CT/B ultrasound showed no fatty liver
• No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia
• Received neoadjuvant/adjuvant chemotherapy

You may not qualify if…

• Missing follow-up information
• Liver lesions (metastases, hemangioma, etc.)
• Poor image quality

Where it is running

• Yunnan Cancer Hospital — Kunming, Yunnan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.